IL-15 DNA (formulated with bupivacaine) (HIV Vaccine) — Pipeline & Regulatory Status

Program Status: Inactive / Discontinued

Reason: Registry status: TERMINATED

Stage at discontinuation: phase_1

Development Phase Discontinued / Inactive Primary Status

Platform Technology DNA Biologic Architecture

Target Indication HIV Pathogen / Antigen

Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority	Status & Details
US FDA	Not Filed / Pre-submission
EMA (Europe)	Not Filed / Pre-submission
Health Canada	Not Filed / Pre-submission
TGA (Australia)	Not Filed / Pre-submission

Scientific Profile & Documentation

Platform Architecture: DNA
Lead Developer: Wyeth is now a wholly owned subsidiary of Pfizer
Next Expected Milestone: See linked ClinicalTrials.gov records for primary completion dates
Analyst & Development Notes: Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation: ClinicalTrials.gov NCT00195312 →

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT00195312 Discontinued / Inactive

Study Evaluating Vaccine in Adults With HIV

Status: Active / Ongoing • Expected Readout: TBD

Milestone Overview

Stage Verification

Discontinued / Inactive confirmed as of 2026-07-10.
Target Milestone

See linked ClinicalTrials.gov records for primary completion dates

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.